Patent application number | Description | Published |
20090306176 | Use Of Low Doses Of Oligonucleotides Antisense To TGF-Beta, VEGF, Interleukin-10, C-Jun, C-Fos Or Prostaglandin E2 Genes In The Treatment Of Tumors - This invention is related to the use of at least one oligonucleotide with a length of from about 8 to about 30 nucleotide building blocks for manufacturing a pharmaceutical preparation for the prophylaxis and/or the treatment of diseases, that are modulated by TGF-beta2, TGF-beta1, TGF-beta3, VEGF, interleukin-10, c-jun, c-fos, and/or prostaglandin E2 in a mammal, wherein said oligonucleotide hybridizes with a messenger RNA of a TGF-beta2, TGF-beta1, TGF-beta3, VEGF, interleukin-10, c-jun, c-fos and/or prostaglandin E2 gene and wherein said preparation comprises said oligonucleotide in a concentration of about 1 microM to about 25 microM. | 12-10-2009 |
20100160208 | Pharmaceutical composition - The invention concerns a pharmaceutical composition comprising at least one stimulator of the immune cell functions and at least one substance inhibiting the cell proliferation and/or inducing cell death. In a preferred embodiment the stimulator of the function of the immune system and/or the immune cells are antagonists of TGF-beta selected from the group of oligonucleotides hybridizing with an area of the messenger RNA and or DNA encoding TGF-beta and the at least one substance inhibiting cell proliferation and/or inducing cell death is selected from the group of temozolomide, nitrosoureas, Vinca alkaloids, antagonists of the purine and pyrimidines bases, cytoststatic active antibiotics, caphthotecine derivatives, anti estrogens, anti-androgens and analogs of gonadotropin releasing hormone. | 06-24-2010 |
20100273705 | Method for inhibiting "Melanoma Inhibitory Activity" MIA - The present invention is directed to peptides, antibodies and antibody fragments inhibiting activity of “Melanoma Inhibitory Activity” (MIA). | 10-28-2010 |
20100286236 | Dosage of oligonucleotides suitable for the treatment of tumors - A method for preventing and/or treating a tumor, the method comprising: intravenously administering an antisense oligonucleotide in an amount of between about 400 to about 800 mg/m | 11-11-2010 |
20110136893 | OLIGONUCLEOTIDE-, PROTEIN AND/OR PEPTIDE-POLYMER CONJUGATES - A conjugate or compound comprising polyethyleneglycol and an oligonucleotide, wherein at least one polyethyleneglycol is linked to the 5′-end of the oligonucleotide and at least one polyethyleneglycol is linked to the 3′-end of the oligonucleotide, wherein the molecular weight of the polyethyleneglycol linked to the 5′- and 3′-end of the oligonucleotide is identical and is <5000 Da, or wherein the molecular weight of the polyethyleneglycol linked to the 5′- and 3′-end of the oligonucleotide is different. | 06-09-2011 |
20120027873 | COMBINATION OF A CHEMOTHERAPEUTIC AGENT AND AN INHIBITOR OF THE TGF-BETA SYSTEM - Pharmaceutical composition comprising a chemotherapeutic agent and a TGF-beta antisense oligonucleotide, wherein the antisense oligonucleotide reduces the sensitivity and IC | 02-02-2012 |
20120208774 | METHOD FOR INHIBITING "MELANOMA INHIBITORY ACTIVITY" MIA - The present invention is directed to peptides, antibodies and antibody fragments inhibiting activity of “Melanoma Inhibitory Activity” (MIA). | 08-16-2012 |
Patent application number | Description | Published |
20090285817 | Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene - A mixture comprising at least one inhibitor or suppressor of the expression of a gene and at least one molecule binding to an expression product of said gene. | 11-19-2009 |
20090306176 | Use Of Low Doses Of Oligonucleotides Antisense To TGF-Beta, VEGF, Interleukin-10, C-Jun, C-Fos Or Prostaglandin E2 Genes In The Treatment Of Tumors - This invention is related to the use of at least one oligonucleotide with a length of from about 8 to about 30 nucleotide building blocks for manufacturing a pharmaceutical preparation for the prophylaxis and/or the treatment of diseases, that are modulated by TGF-beta2, TGF-beta1, TGF-beta3, VEGF, interleukin-10, c-jun, c-fos, and/or prostaglandin E2 in a mammal, wherein said oligonucleotide hybridizes with a messenger RNA of a TGF-beta2, TGF-beta1, TGF-beta3, VEGF, interleukin-10, c-jun, c-fos and/or prostaglandin E2 gene and wherein said preparation comprises said oligonucleotide in a concentration of about 1 microM to about 25 microM. | 12-10-2009 |
20110136893 | OLIGONUCLEOTIDE-, PROTEIN AND/OR PEPTIDE-POLYMER CONJUGATES - A conjugate or compound comprising polyethyleneglycol and an oligonucleotide, wherein at least one polyethyleneglycol is linked to the 5′-end of the oligonucleotide and at least one polyethyleneglycol is linked to the 3′-end of the oligonucleotide, wherein the molecular weight of the polyethyleneglycol linked to the 5′- and 3′-end of the oligonucleotide is identical and is <5000 Da, or wherein the molecular weight of the polyethyleneglycol linked to the 5′- and 3′-end of the oligonucleotide is different. | 06-09-2011 |